The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Promising ROd-cone DYstrophy Gene therapY (PRODYGY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05748873
Recruitment Status : Recruiting
First Posted : March 1, 2023
Last Update Posted : June 1, 2023
Sponsor:
Information provided by (Responsible Party):
SparingVision

Brief Summary:
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm controlled double-masked randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.

Condition or disease Intervention/treatment Phase
Retinitis Pigmentosa Drug: SPVN06 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2)
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2). In Cohorts 5 and 6 of Step 2, subjects and the designated study personnel will be masked to subject's dose assignment. Cohort 4 (untreated group) will be unmasked.
Primary Purpose: Treatment
Official Title: A Phase I/II Study to Assess the Safety and Tolerability of a Single Subretinal Administration of SPVN06 Gene Therapy in Subjects With Rod-Cone Dystrophy (RCD) Due to a Mutation in the RHO, PDE6A, or PDE6B Gene
Actual Study Start Date : April 12, 2023
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2029


Arm Intervention/treatment
Experimental: Step 1 : SPVN06 dose 1
Participants will receive a single subretinal injection of SPVN06 Dose 1 on Day 0.
Drug: SPVN06
AAV-RdCVF-RdCVFL

Experimental: Step 1 : SPVN06 dose 2
Participants will receive a single subretinal injection of SPVN06 Dose 2 on Day 0
Drug: SPVN06
AAV-RdCVF-RdCVFL

Experimental: Step 1 : SPVN06 dose 3
Participants will receive a single subretinal injection of SPVN06 Dose 3 on Day 0
Drug: SPVN06
AAV-RdCVF-RdCVFL

Experimental: Step 2 : SPVN06 Dose Recommended 1
Participants will receive a single subretinal injection of SPVN06 recommended dose 1 on Day 0
Drug: SPVN06
AAV-RdCVF-RdCVFL

Experimental: Step 2 : SPVN06 Dose Recommended 2
Participants will receive a single subretinal injection of SPVN06 recommended dose 2 on Day 0
Drug: SPVN06
AAV-RdCVF-RdCVFL

No Intervention: Step 2 : Control group



Primary Outcome Measures :
  1. Evaluation of the safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene, 12 months after administration of gene therapy. [ Time Frame: Baseline to 12 months after administration of gene therapy ]
    Incidence and severity of systemic and ocular AEs and SAEs


Secondary Outcome Measures :
  1. Evaluation of the long-term safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene, up to 5 years after treatment administration. [ Time Frame: up to 5 years after treatment ]
    Incidence and severity of systemic and ocular AEs and SAEs

  2. Evaluation of viral shedding and bio-dissemination up to 6 months after treatment administration. [ Time Frame: up to 6 months after treatment ]
    Quantification of viral DNA copies in tears (viral shedding) and in blood (bio-dissemination)

  3. Evaluation of the immune response against the viral vector of SPVN06 up to 5 years after treatment administration. [ Time Frame: up to 5 years after treatment ]
    Titration of total antibodies against the viral capsid

  4. Evaluation of preliminary efficacy as assessed by visual acuity [ Time Frame: up to 5 years after treatment ]
    BCVA change from baseline (EDTRS chart)

  5. Evaluation of preliminary efficacy as assessed by optical coherence tomography [ Time Frame: up to 5 years after treatment ]
    Anatomical change from baseline (SD-OCT)

  6. Evaluation of preliminary efficacy as assessed by color vision [ Time Frame: up to 5 years after treatment ]
    Change from baseline of parameters collected by Cambridge and Lanthony tests

  7. Evaluation of preliminary efficacy as assessed by visual field [ Time Frame: up to 5 years after treatment ]
    Change from baseline of static perimetry, kinetic perimetry and microperimetry

  8. Evaluation of preliminary efficacy as assessed by retinal sensitivity [ Time Frame: up to 5 years after treatment ]
    Change from baseline of parameters collected by full-field electroretinography

  9. Evaluation of preliminary efficacy as assessed by retinal sensitivity [ Time Frame: up to 5 years after treatment ]
    Change from baseline of parameters collected by FST

  10. Evaluation of preliminary efficacy as assessed by FAF [ Time Frame: up to 5 years after treatment ]
    Change from baseline of parameters collected by fundus autofluorescence

  11. Evaluation of preliminary efficacy as assessed by adaptive optics imaging [ Time Frame: up to 5 years after treatment ]
    Change from baseline of parameters collected by RTX1 and AOSLO

  12. Evaluation of preliminary efficacy as assessed by quality of life [ Time Frame: up to 5 years after treatment ]
    Change from baseline of parameters collected by VFQ-25

  13. Evaluation of preliminary efficacy as assessed by quality of life [ Time Frame: up to 5 years after treatment ]
    Change from baseline of parameters collected by ViSIO-PRO


Other Outcome Measures:
  1. Exploratory objective [ Time Frame: up to 5 years after treatment ]
    Collect and store urine and blood (in addition to the body fluids used for the assessment of viral shedding and bio-dissemination) for further exploration of biomarkers of medical interest not already identified at time of protocol submission.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects will be eligible to participate in this study only if all the following criteria apply:

  1. Able to give signed informed consent and comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  2. Age ≥18 years at the time of ICF signature.
  3. Subjects of either gender previously diagnosed with advanced RCD due to biallelic mutations in the rod cGMP phosphodiesterase 6 beta (PDE6B) or rod cGMP phosphodiesterase alpha (PDE6A) genes, or due to a monoallelic dominant mutation in the rhodopsin (RHO) gene. The genotyping results must be documented before the initiation of the Screening Visit. Subjects should be retested by the investigator if their genotyping tests were not performed within the 3 previous years, or if they were not performed by an accredited laboratory. In this case, the screening period can be prolonged for 2 additional weeks to allow time to generate genotyping results.
  4. Advanced stage is defined as a stage of the natural history of the disease where both distance visual acuity and visual field are affected in both eyes. Substages within the advanced stage are defined as follows (monocular measurements, horizontal axis of isopter III4e for the visual field):

    • Severe stage is defined by both a BCVA below or equal to 20/200 and above or equal to 20/400, and a visual field below or equal to 20 degrees (subjects of Cohorts 1 to 3)
    • Intermediate stage is defined by both a BCVA below or equal to 20/40 and above 20/200, and a visual field below or equal to 20 degrees (subjects of Cohorts 4 to 6)
  5. Regardless of the severity of the disease, the difference in visual acuity between the two eyes of a given subject should be equal to or below 0.3 logarithm of the minimal angle (LogMAR) (≤ 3 ETDRS lines).
  6. Clinical diagnosis of RCD based on past medical and family history, mid-peripheral visual field dysfunction, photopsia, night blindness (nyctalopia), and fundoscopic appearance (including but not restricted to bone spicule pigmentation, attenuation of the retinal vessels, and waxy pallor of the optic nerve).
  7. Diagnosis of RCD is confirmed on prior full-field ERG (any previously performed ERG is acceptable).
  8. Documented preservation of cone inner and outer segments considered good enough by the investigator for the subject to be included in the study.
  9. Negative serum pregnancy test for women of childbearing potential (please refer to Schedule of Assessments for details).
  10. Women of childbearing potential (WOCBP) and men and/or their partner(s) of childbearing potential must agree to use a highly effective contraceptive method. This applies to the time period between ICF signature and 12 months after SPVN06 SRI. The definition of highly effective contraceptive methods follows CTFG recommendations. Highly effective contraceptive methods are limited to:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Intravaginal
      • Transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Injectable
      • Implantable
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Sexual abstinence
  11. Subjects must be affiliated to a health security system, if they are included in a clinical site based in France (per law).
  12. No out-of-range values for clinical laboratory tests, however, if outside, must be considered as non-clinically relevant by the investigator using a multidisciplinary approach and compatible with a participation in the clinical study.
  13. 12-lead electrocardiogram within normal limits, however, when outside, must be documented by the investigator using a multidisciplinary approach as not clinically relevant and compatible with a participation in the clinical study.
  14. Physical examination without any clinical findings of clinical relevance (per medical/anesthesia staffs judgment) that could compromise participation in the clinical study or could affect the collection and/or evaluation of the study parameters. The findings of clinical relevance considered as contraindications to SPVN06 treatment include, but are not limited to, pulmonary pathology such as COPD, asthma, cardiac conditions such as congestive heart failure or valve disease, renal issues such as renal insufficiency and endocrine issues such as diabetes.

Exclusion Criteria:

Subjects are not eligible to participate in this study if any of the following criteria apply:

  1. Subjects with prior administration of any gene therapy or any previous treatment with stem cell therapy for ocular or non-ocular disease.
  2. Subjects participating in another clinical trial and receiving an investigational medicinal product (IMP) within 5 half-lives or 90 days prior to the injection of SPVN06.
  3. Subjects with RCD due to any mutation in genes other than those listed in the inclusion criteria.
  4. Subjects with systemic disease or other pathology not related to their diagnosis of RCD, and whose symptoms or associated treatments may affect vision, for example cancers or pathology of the central nervous system.
  5. Subjects with narrow irido-corneal angles or any other medical situation contraindicating pupillary dilation.
  6. Subjects known to be allergic to any of the delivery vehicle constituents or to any other drugs planned to be used during the clinical study.
  7. Subjects with known allergies to corticosteroids, or who will be unable to tolerate the corticosteroid regimen as described in the protocol
  8. Subjects with systemic disease or other medical or psychiatric conditions that preclude safe participation in the study.
  9. Subjects receiving immunosuppressive therapies, other than the immune modulating regimen described in this protocol, or any other therapy known to influence the immune system including but not limited to steroid implants, cytostatics, interferons, tumor necrosis factor (TNF)-binding proteins, drugs acting on immunophilins, or antibodies with known impact on the immune system.
  10. Subjects of reproductive potential unwilling to use effective contraception starting right after ICF signature and for 12 months after SPVN06 SRI.
  11. Subjects who are pregnant or breastfeeding.
  12. Subjects who are unwilling or unable (based on the investigator's judgment) to comply with the study protocol.
  13. Subjects with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the investigator, would make them unsuitable for the study.
  14. Subjects positive for human immunodeficiency virus (HIV) or any other systemic immunocompromising disease.
  15. Subjects who have undergone, within 6 months before inclusion, any significant ocular surgery (per investigator's judgment) that could interfere with the evaluation of SPVN06 study objectives.
  16. Presence of eye disorders that could interfere with the assessment of visual acuity and/or any other ocular assessments, including SD-OCT, during the study.
  17. Presence of any systemic or ocular diseases, other than non-syndromic retinitis pigmentosa (RP), that can cause vision loss.
  18. Prior vitrectomy or vitreomacular surgery.
  19. Presence of vitreomacular adhesion or traction, epiretinal membrane macular pucker or macular hole, evident by ophthalmoscopy and/or SD-OCT examinations and assessed by the investigator to significantly affect central vision.
  20. Current evidence of retinal detachment assessed by the investigator to significantly affect central vision.
  21. Active ocular inflammation or recurrent history of idiopathic or autoimmune-associated uveitis.
  22. Subjects with presence of any suspected or active ocular or periocular infection (conjunctivitis, keratitis, scleritis, endophthalmitis).
  23. Subjects with history of glaucoma.
  24. Subjects with uncontrolled intraocular pressure (IOP).
  25. Subjects with active cancer or currently receiving any therapy for cancer treatment.
  26. Subjects with any history of ocular malignancy.
  27. Subjects with a clinically significant cardiac disease on routine clinical examination (history, physical examination), or known congestive heart failure, myocardial infarction, clinically significant valvular heart disease, clinically significant cardiac rhythm or conduction abnormalities.
  28. Subjects with unstable/uncontrolled hypertension, defined by national recommendations.
  29. Subjects with pulmonary dysfunction or severe obstructive pulmonary disease.
  30. Subjects with active tuberculosis.
  31. Subjects with liver or renal insufficiency.
  32. Subjects with unstable endocrine disease, including unstable diabetes or thyroid disease.
  33. Subjects with active Hepatitis B or Hepatitis C.
  34. Subjects with clinically active infection of herpetic diseases, including herpes simplex virus, varicella zoster virus (VZV), cytomegalovirus (CMV) or EBV.
  35. Subjects with known history of ocular infection with herpes simplex virus.
  36. Subjects with active (extraocular) infection (requiring or not the prolonged or chronic use of antimicrobial agents).
  37. Immunocompromised subjects with previous solid organ or bone marrow transplant.
  38. Subjects who receive a live vaccine less than 4 weeks prior to SPVN06 injection
  39. Subjects who were infected by COVID-19 less than 2 weeks prior to SPVN06 injection.
  40. Subjects who have recently received (less than 4 weeks) or plan to receive a COVID-19 vaccination.
  41. Incapacitated subjects, as defined by national laws.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05748873


Contacts
Layout table for location contacts
Contact: SparingVision +33143462060 info@sparingvision.com
Contact: Medical Director

Locations
Layout table for location information
United States, Pennsylvania
UPMC Eye Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Natalie Anthony    412-647-5756    anthonynl2@upmc.edu   
Contact: Rhonda Dahlstrom    412-647-5756    dahlstromrj@upmc.edu   
Principal Investigator: Joseph Martel, MD         
France
CHNO XV-XX Paris - CIC 1423 Recruiting
Paris, France, 75012
Contact: Berthe Pom    +33635230695    bpom@15-20.fr   
Principal Investigator: Isabelle Audo, MD, PhD         
Sponsors and Collaborators
SparingVision
Layout table for additonal information
Responsible Party: SparingVision
ClinicalTrials.gov Identifier: NCT05748873    
Other Study ID Numbers: SPVN06-CLIN-01
First Posted: March 1, 2023    Key Record Dates
Last Update Posted: June 1, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by SparingVision:
RHO
PDE6A
PDE6B
Pathogenic Mutation
Retinal Disease
Eye Disease
Rod-Cone Dystrophy
Gene Therapy
Retinal Dystrophies
Retinal Degeneration
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinitis
Retinitis Pigmentosa
Cone Dystrophy
Cone-Rod Dystrophies
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn